Opioids and opiates inhibit gastrointestinal functions via , ␦, and receptors. Although agonists of the ␦ opioid receptor (DOR) suppress motility and secretion, little is known about the localization and regulation of DOR in the gastrointestinal tract. METHODS: We studied mice in which the gene that encodes the enhanced green fluorescent protein (eGFP) was inserted into Oprd1, which encodes DOR, to express an approximately 80-kilodalton product (DOReGFP). We used these mice to localize DOR and to determine how agonists regulate the subcellular distribution of DOR. RESULTS: DOReGFP was expressed in all regions but was confined to enteric neurons and fibers within the muscularis externa. In the submucosal plexus, DOReGFP was detected in neuropeptide Y-positive secretomotor and vasodilator neurons of the small intestine, but rarely was observed in the large bowel. In the myenteric plexus of the small intestine, DOReGFP was present in similar proportions of excitatory motoneurons and interneurons that expressed choline acetyltransferase and substance P, and in inhibitory motoneurons and interneurons that contained nitric oxide synthase. DOReGFP was present mostly in nitrergic myenteric neurons of colon. DOReGFP and opioid receptors often were co-expressed. DOReGFP-expressing neurons were associated with enkephalin-containing varicosities, and enkephalin-induced clathrin-and dynamin-mediated endocytosis and lysosomal trafficking of DOReGFP. DOReGFP replenishment at the plasma membrane was slow, requiring de novo synthesis, rather than recycling. CONCLU-SIONS: DOR localizes specifically to submucosal and myenteric neurons, which might account for the ability of DOR agonists to inhibit gastrointestinal secretion and motility. Sustained down-regulation of DOReGFP at the plasma membrane of activated neurons could induce long-lasting tolerance to DOR agonists.
O pioids and opiates inhibit gastrointestinal functions via G-protein-coupled , ␦, and opioid receptors (MOR, DOR, and KOR). 1, 2 Opiates that activate MOR, DOR, and KOR inhibit intestinal peristalsis in the guinea pig, 3, 4 and opioid-receptor antagonists disrupt peristaltic contractions in guinea pig, mouse, and rat, suggesting that endogenous opioids modulate this reflex. [3] [4] [5] [6] Opioidreceptor agonists also inhibit secretion from the rat jejunum. 7 The mechanisms underlying these actions are of interest because they mediate constipation, which is the major limiting side effects of opiate analgesics.
Anatomic and pharmacologic studies provide insight into the location and function of opioid receptors in the gut. However, it is unclear whether opioids and opiates exert their effects by activating receptors on enteric neurons or other cell types within the gut, or act centrally. Although the location and activation of MOR in enteric neurons have been studied extensively because of its importance in morphine-induced constipation, 8 less is known about the distribution and activation of DOR and KOR in the gastrointestinal tract. Electrophysiological studies have indicated that opioids regulate enteric neurons by DOR-and MOR-dependent mechanisms. 9 However, it is not known whether these receptors are coexpressed by enteric neurons, where they may respond to the same agonists and could interact.
Agonists promote endocytosis of many G-protein-coupled receptors in neurons, including opioid receptors, and redistribution of receptors to endosomes is a hallmark of activation. Endocytosis attenuates G-protein-dependent signaling by depleting receptors from the cell surface, but also activates G-protein-independent signaling by recruiting receptors and adaptor proteins, such as ␤-arrestins, to endosomes. 10 Endosomal sorting targets receptors to the plasma membrane, where recycling mediates resensitization, or to lysosomes, where degradation down-regulates signaling. Activated DOR traffics to lysosomes, 11, 12 but also can recycle. 13 Nothing is known about the mechanism and pathway of DOR trafficking in enteric neurons.
We localized DOR in enteric neurons and determined the mechanism and pathway of agonist-stimulated trafficking of DOR. To enable specific detection and permit direct observation of receptor trafficking in real time, we studied mice in which enhanced green fluorescent protein (eGFP) was knocked into the DOR gene Oprd1. 14 We detected DOReGFP in specific populations of submucosal and myenteric neurons, some of which co-expressed MOR. Agonists stimulated clathrin-and dynamin-mediated endocytosis of DOR, which trafficked via early endosomes to lysosomes, and repletion of cell surface receptors required de novo synthesis.
Materials and Methods
See the Supplementary Materials and Methods section for complete methodologic details, and Supplementary Table 1 for sources and dilutions of antibodies.
Animals
Mice expressing DOR with C-terminal eGFP have been characterized. 12,14 -16 Mice (male and female, 20 -30 g) were anesthetized with tribromoethanol (Avertin, Sigma, St. Louis, MO; 250 mg/kg, intraperitoneally [IP] ) and killed by bilateral thoracotomy. The University of California San Francisco Institutional Animal Care and Use Committee approved all procedures.
Western Blotting
Tissue extracts (60 g protein) were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and DOReGFP was detected by Western blotting for GFP.
Immunofluorescence
Sections and whole-mounts of enteric ganglia were incubated with primary antibodies, washed, and incubated with fluorescent secondary antibodies (1 h, room temperature). To facilitate detection of neuropeptides in the soma, mice were treated with colchicine (2.5 mg/kg, IP) 6 hours before tissue collection. To facilitate detection of DOReGFP-positive submucosal neurons, mice were treated with the DOR agonist SNC80 (10 mg/kg, subcutaneously [SC]) 30 minutes before tissue collection, which concentrated the receptor in endosomes where it was readily detected. This strategy was not necessary for detecting DOReGFP in myenteric neurons.
DOReGFP Trafficking
To examine DOR trafficking in vivo, mice were treated with SNC80 (10 mg/kg, SC), and whole-mounts of myenteric and submucosal plexuses were prepared at various times. To examine trafficking in organotypic cultures, ileal segments were opened, pinned mucosa-down onto silicone-lined dishes, and equilibrated (1 h, 37°C) in Krebs' buffer containing nicardipine (1 mol/L) and tetrodotoxin (1 mol/L). Tissues were stimulated with SNC80 or Met-enkephalin (10, 100 nmol/L) for 1 hour at 4°C, washed, incubated at 37°C for varying times to allow DOR trafficking to occur, and were fixed and processed for immunofluorescence. To induce endogenous opioid release, tissues were stimulated with KCl (50 mmol/L; 2-min wash, 30-min recovery) in buffer containing nicardipine, bestatin, captopril, leupeptin, phosphoramidon, and thiorphan (10 mol/L). To examine trafficking in isolated neurons, myenteric neurons were dispersed enzymatically from the ileum or distal colon, and were cultured for 7-10 days. 17 Cultured neurons were stimulated with DOR agonists, fixed, and processed for immunofluorescence.
Imaging
Specimens were examined using a Zeiss LSM510 META confocal microscope (Carl-Zeiss, Thornwood, NY). Expression of GFP relative to the total neuronal population and functional neuronal subtypes was determined by co-labeling with neurochemical markers. 18, 19 
Statistical Analysis
Data are expressed as the mean Ϯ standard error of the mean and were analyzed using the Student t test or 1-way analysis of variance with the Newman-Keuls or Bonferroni post hoc test. A P value of less than .05 was considered significant.
Results

DOR Is Expressed in Enteric Neurons
DOReGFP immunoreactivity (IR) was detected as a prominent band of approximately 80 kilodaltons in all regions ( Figure 1A) , consistent with the combined sizes of DOR and eGFP. 12 Other immunoreactive proteins may correspond to oligomers or degradation products. No signal was detected in tissues from wild-type mice (not shown). We localized DOReGFP in sections by indirect immunofluorescence using GFP antibody to amplify the signal. DOReGFP-IR was detected in the esophagus, corpus, antrum, gall bladder, duodenum, ileum, cecum, proximal colon, and distal colon, where it was localized to enteric ganglia and nerve fibers ( Figure 1B ). Within ganglia, DOReGFP-IR colocalized with the neuronal marker PGP9.5 in a subset of myenteric and submucosal neurons, but it did not colocalize with glial fibrillary acidic protein, which identifies enteric glial cells (not shown). Nerve fibers 
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containing DOReGFP-IR projected along the axes of the circular and longitudinal muscle layers of the muscularis externa ( Figure 1B) Figure 1B ).
DOR Is Expressed by Secretomotor/Vasodilator Submucosal Neurons
Supplementary Table 2 reports the proportions of submucosal neurons co-expressing DOReGFP-IR and neurochemical markers. DOReGFP-IR colocalized with PGP9.5-IR in submucosal neurons, but there were marked differences in the proportions of neurons expressing DOReGFP-IR in the small and large intestines. In the duodenum and ileum, DOReGFP-IR was detected in most submucosal neurons, whereas few neurons expressed DOReGFP-IR in the cecum and colon. We estimate by extrapolation from neurochemical coding studies 18 that approximately 50% of all submucosal neurons of the ileum express DOReGFP. In the ileum, 90% of neurons expressing DOReGFP-IR co-expressed neuropeptide Y-IR (identifies noncholinergic secretomotor and vasodilator neurons 18 ) (Supplementary Figure 1A) . Of neurons expressing DOReGFP-IR, 8% co-expressed choline acetyl transferase (ChAT)-IR (identifies cholinergic secretomotor neurons) and 11% co-expressed somatostatin (SOM)-IR (localized to cholinergic submucosal neurons of the ileum) (Supplementary Figure 1A) , consistent with the minimal colocalization of ChAT and DOReGFP. In the distal colon, there was a smaller degree of overlap between DOReGFP-IR and neuropeptide Y-IR (39%) than in the ileum, and DOReGFP-IR and ChAT-IR rarely were colocalized (10%) (Supplementary Figure 1B) . A substantial proportion of submucosal neurons in the large intestine that expressed DOReGFP-IR co-expressed NOS-IR (cecum, 96%; proximal colon, 33%; distal colon, 79%; Figure 2C ). Although most submucosal neurons of the cecum expressed NOS-IR at a low level, those neurons expressing DOReGFP-IR had intense signals for NOS-IR (Supplementary Figure 1C) . The relative mean fluorescence intensity of NOS-IR in DOReGFP-negative neurons was 0.50 Ϯ 0.03 (n ϭ 188 neurons) and in DOReGFP-positive neurons was 1.00 Ϯ 0.03 (n ϭ 35 neurons). These neurons were unipolar.
DOR Is Expressed by Nitrergic and Cholinergic Myenteric Neurons
Supplemental Table 3 reports the proportions of myenteric neurons co-expressing DOReGFP-IR and neurochemical markers. Intense DOReGFP-IR was detected at the plasma membrane of the soma and axons of a subset of myenteric neurons, with little intracellular signal (Figure 2) . In all regions (antrum to distal colon), approximately 50% of all PGP9.5-IR myenteric neurons co-expressed DOReGFP-IR, with the exception of the proximal colon where only approximately 38% of myenteric neurons were DOReGFP positive ( Figure 2A ). There were marked differences in the neuronal subtypes that expressed DOReGFP in the small and large intestine. The proportion of DOReGFP-IR neurons co-expressing NOS-IR (identifies inhibitory motoneurons and interneurons) was 44%-53% in the small intestine ( Figure 2B ) and 66%-95% in the large intestine (Supplementary Figure 2A) . The proportion of DOReGFP-IR neurons co-expressing ChAT-IR (identifies cholinergic excitatory motoneurons, interneurons, and IPANs) was 41%-44% in the small intestine ( Figure  2C ) and only 9%-30% in the large intestine (Supplementary Figure 2B ). In the small and large intestines, DOReGFP-IR was not detected in large ChAT-IR neurons, which probably are IPANs. DOReGFP-IR was not detected in neurons with Dogiel type II morphology that expressed neurofilament M-IR (identifies IPANs and other neurons in the mouse myenteric plexus 19 ) in any of the regions examined ( Figure 2D , Supplementary Figure 2C ). DOReGFP-IR did not colocalize with the IPAN marker calcitonin gene-related peptide-IR (not shown). 19, 20 
DOR and SOM Receptor Somatostatin Receptor 2A Are Expressed by Distinct Nitrergic Myenteric Neurons
Functional studies of peristalsis suggest that DOR is co-expressed with SOM receptor somatostatin receptor 2A (SSTR2A) by inhibitory motoneurons containing NOS and vasoactive intestinal polypeptide in mouse colon. 5 SSTR2A-IR colocalizes with NOS-IR and vasoactive intestinal polypeptide-IR in myenteric neurons, suggesting overlap with DOReGFP-IR. 21, 22 To examine this possibility, we simultaneously localized DOReGFP, SSTR2A, and NOS in myenteric plexus whole-mounts of large intestine. There was no detectable colocalization of DOReGFP-IR and SSTR2A-IR ( Figure 2E ). Although DOReGFP-IR and SSTR2A-IR were colocalized extensively with NOS-IR, triple labeling indicated that the 2 receptors were present in distinct populations of NOS-IR neurons. Neurons coexpressing SSTR2A-IR and NOS-IR were larger (diameter, 27.98 Ϯ 0.74 m; 56 neurons) than neurons co-expressing DOReGFP-IR and NOS-IR (diameter, 20.80 Ϯ 0.36 m; 187 neurons; P Ͻ .0001). Neurons expressing NOS-IR mostly co-expressed DOReGFP-IR (76% distal colon), with the remaining neurons either co-expressing SSTR2A-IR (17%) or only NOS-IR (7%). SOM-IR was detected in few myenteric neurons, which were characterized by intense labeling of Golgi-like structures and by filamentous morphology (Supplementary Figure 2D) . A small proportion (3%-4%) of DOReGFP-IR neurons co-expressed SOM-IR in the ileum and distal colon, where SOM is present in a subset of descending interneurons. 5, 19 The minimal overlap between DOR and SSTR2A or SOM is at variance with predictions of pharmacologic studies.
DOR Is Co-expressed With Substance P but Not the Neurokinin 1 Receptor in Myenteric Neurons
Tachykinins are excitatory peristaltic neurotransmitters. 5 Of DOReGFP-IR myenteric neurons, 33% coexpressed substance P (SP)-IR in the ileum and 25% coexpressed SP-IR in the distal colon of colchicine-treated mice (Supplementary Figure 2E) . In the distal colon, only 1% of DOReGFP-IR neurons co-expressed neurokinin 1 receptor-IR (Supplementary Figure 2F) . Neurokinin 1 re- 
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ceptor-IR neurons mainly were multipolar and larger than DOReGFP-IR neurons. The colocalization of DOR with SP in ascending interneurons and excitatory circular muscle motoneurons 19 suggests that DOR is appropriately located to inhibit SP release and indirectly modulate neurokinin 1-receptor activation, but DOR could not directly regulate neurokinin 1 receptor.
DOR and MOR Are Co-expressed by Enteric Neurons
To examine DOR/MOR colocalization, we localized DOReGFP-IR and detected MOR by using a characterized MOR-specific antibody 8 that does not stain tissue from MOR-deficient mice 16 and by studying uptake of the MOR-selective agonist Cy3-[Lys 7 , Cys 8 ]dermorphin (Cy3-dermorphin). In myenteric ganglia of the distal colon, MOR-IR was localized to a subset of neurons and to myenteric interstitial cells of Cajal ( Figure 3A) . Approximately 77%-85% of all DOReGFP-IR myenteric neurons co-expressed MOR-IR, and 57%-61% of MOR-IR neurons co-expressed DOReGFP ( Figure 3A and B) . However, MOR-IR also was detected in large neurons, probably IPANs, that did not express DOReGFP-IR. Cy3-dermorphin (100 nmol/L) bound and trafficked to endosomes of myenteric neurons, many of which also expressed DOReGFP-IR ( Figure 3C ), although the extent of colocalization was not quantified. Naloxone (1 mol/L) abolished binding of Cy3-dermorphin, confirming specific interaction with MOR (not shown). MOR-IR was detected in submucosal neurons of ileum and distal colon, many of which also expressed DOReGFP-IR ( Figure 3D ), although colocalization was not quantified. There were marked differences in the subcellular localization of DOR and MOR in some neurons where these receptors were coexpressed. In all neurons, DOReGFP was localized predominantly to the plasma membrane. However, MOR-IR was either mostly intracellular ( Figure 3A ) or mostly at the plasma membrane ( Figure 3B ).
Enkephalinergic Varicosities Innervate DOR Myenteric Neurons
We examined the proximity between DOR and the endogenous agonist enkephalin and determined whether endogenous agonists could activate DOR. Enkephalin IR was detected in varicosities of fibers surrounding the soma and neurites of DOReGFP-IR neurons, as well as neurons that did not express DOReGFP-IR, in the myenteric ( Figure 4A ) and submucosal (not shown) plexuses of ileum and colon. Enkephalinergic varicosities also were associated intimately with nerve fibers containing DOReGFP-IR in the circular muscle and deep muscular plexus ( Figure 4A, right panel) . Enkephalin-IR and DOReGFP-IR did not colocalize in the soma of myenteric ( Figure 4A ) or submucosal (not shown) neurons. To examine whether endogenous opioids activate DOR, we depolarized organotypic preparations of distal colon using KCl, which induces neuropeptide release, 17 and examined the subcellular distribution of DOReGFP-IR. KCl induced endocytosis of DOReGFP-IR ( Figure 4B and C) , indicating receptor activation. The DOR-selective antagonist naltrindole (100 nmol/L) abolished KCl-induced endocytosis.
Agonists Induce Clathrin-and DynaminDependent DOR Endocytosis
We examined agonist-induced DOR trafficking in myenteric neurons in vivo, in organotypic cultures, and in isolated neurons.
Mice were treated with SNC80 (10 mg/kg SC) or vehicle (control), and DOReGFP-IR was localized in myenteric and submucosal plexus whole-mounts. DOReGFP-IR was confined to the plasma membrane of myenteric and submucosal neurons from vehicle-treated mice ( Figure 4D , myenteric plexus). Within 10 -30 minutes after SNC80 treatment, DOReGFP-IR was detected in endosomes in the soma and axons of myenteric ( Figure 4D ) and submucosal (not shown) neurons.
To examine the precise timing and concentration dependence of DOR trafficking, we incubated organotypic whole-mounts of distal colon with SNC80 (10, 100 nmol/ L), Met-enkephalin (100 nmol/L), or vehicle (0 -120 min, 37°C). In vehicle-treated preparations, DOReGFP-IR was confined to the plasma membrane ( Figure 4D ). SNC80 induced receptor clustering at the plasma membrane within 10 minutes and maximal internalization within 30 -60 minutes ( Figure 4D ). Quantitative analysis indicated that 90.4% Ϯ 0.7% (89 neurons) of total DOReGFP-IR was at the plasma membrane in unstimulated neurons, and that 42.7% Ϯ 5.1% (22 neurons) of total DOReGFP-IR was at the plasma membrane 60 minutes after SNC80 treatment (100 nmol/L, Supplementary Figure 3A) . Met-enkephalin also stimulated DOReGFP internalization ( Figure 4D ). Both SNC80 and Met-enkephalin induced DOR-eGFP endocytosis in the presence of tetrodotoxin (100 nmol/L), suggesting a direct action of these agonists on the DOReGFP receptor. Naltrindole abolished endocytosis (not shown), confirming selectivity.
By studying myenteric neurons in culture, we evaluated DOReGFP trafficking in the soma and neurites of the same neurons in real time. DOReGFP-IR was detected in 46% of PGP9.5-positive myenteric neurons in culture (26 of 57 neurons), indicating retained expression (Supplementary Figure 3B ). In unstimulated neurons, DOReGFP was distributed uniformly at the plasma membrane of the soma and neurites ( Figure 4D, Supplementary Figure  3B ). SNC80 and Met-enkephalin (100 nmol/L) induced DOReGFP internalization, detected by live imaging of DOReGFP and by immunofluorescence detection of GFP. Within 10 minutes, DOReGFP was clustered at the plasma membrane of the soma and neurites, and after 30 minutes DOReGFP was redistributed to endosomes and depleted from the plasma membrane ( Figure 4D , Supplementary Figure 3B ). Naltrindole prevented SNC80-stimulated (Supplementary Figure 3C) and Met-enkephalinstimulated (not shown) trafficking, confirming specific activation of DOR.
To examine the mechanism of DOR endocytosis, we treated organotypic cultures with hypertonic sucrose (0.45 mol/L, which blocks clathrin-mediated endocytosis 17 ), or Dynasore (80 mol/L, which inhibits dynamin 
. Localization of DOR and enkephalin (ENK), and opioid-induced activation of DOR in the myenteric plexus. (A) ENK-IR (red) varicosities were associated intimately with DOReGFP-IR (green) in nerve fibers in circular muscle (CM) and deep muscular plexus (DMP) (arrowheads). DOReGFP-IR was not colocalized with ENK-IR in myenteric neurons (MP, arrowheads with asterisks, right panel). (B) KCl but not vehicle stimulated
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guanosine triphosphatase 23 ). Sucrose and Dynasore inhibited SNC80-evoked endocytosis of DOReGFP-IR in whole-mounts ( Figure 5 ). Sucrose or Dynasore alone were without effect. These findings were confirmed using live imaging of cultured neurons (not shown).
DOR Traffics via Early Endosomes to Lysosomes and Does Not Recycle
To examine the subcellular pathway of DOR trafficking, we simultaneously localized DOReGFP with early endosomal antigen 1 (identifies early endosomes), and LAMP1 or LysoTracker (identify lysosomes). In cultured myenteric neurons, Met-enkephalin stimulated redistribution of DOReGFP-IR to early endosomal antigen 1-positive early endosomes within 10 -30 minutes in the soma ( Figure 6A ) and in neurites (Supplementary Figure 3D) . After 60 -120 minutes, DOR-GFP had traversed the endosomal system and was detected in lysosomes of the soma ( Figure 6B ). Although we did not detect lysosomes in the neurites using LysoTracker or LAMP1 antibodies (not shown), after 60 minutes DOReGFP was detected in vesicles in neurites that were distinct from early endosomes (Supplementary Figure 3D) . DOReGFP-IR also colocalized with LAMP1 in the soma of myenteric neurons of whole-mounts 60 -120 minutes after administration of SNC80 to the intact mouse, and DOReGFP was still detected in lysosomes after 16 hours ( Supplementary Figure 3E) . Because DOR traffics to lysosomes and there are no prominent intracellular stores, DOR replenishment at the plasma membrane probably requires receptor synthesis. To examine this process, cultured neurons were incubated briefly with Met-enkephalin (100 nmol/L, 10 min) or vehicle, washed, and then recovered in agonist-free medium. Met-enkephalin, but not vehicle, induced translocation of DOReGFP to endosomes and lysosomes within 0.5-2 hours. DOReGFP-IR was replenished at the plasma membrane within 6 -16 hours ( Figure 6C ). Cycloheximide (70 mol/L) did not affect DOReGFP-IR endocytosis, but prevented recovery of receptor at the plasma membrane ( Figure 6D and E), indicating a requirement for new receptor synthesis. 
Discussion
We report a detailed examination of the expression and regulation of DOR in the enteric nervous system. DOReGFP knock-in mice, previously used to study DOR in sensory and central neurons, 12,14 -16 enabled specific detection, avoiding concerns about antibody selectivity. DOR is expressed by secretomotor submucosal neurons, and inhibitory nitrergic and excitatory cholinergic/tachykinergic myenteric motoneurons. Agonists induce clathrin-and dynamin-mediated endocytosis of DOR in the soma and axons, although DOR traffics to lysosomes only in the soma, suggesting differences in the fate and regulation of the receptor in the soma and axons. Restoration of surface DOR is slow, requiring de novo synthesis. Agonists may activate DOR on myenteric neurons to suppress peristalsis, [3] [4] [5] and the prolonged intracellular retention of activated DOR may induce sustained unresponsiveness of activated neurons.
Location and Function of DOR in Secretomotor Neurons of the Submucosal Plexus
We report that most ileal submucosal neurons express DOR, in particular neuropeptide Y-positive, noncholinergic, secretomotor neurons. 18 In contrast, DOR rarely is expressed in colonic submucosal neurons, where it is confined to nitrergic neurons. These findings support the localization of DOR to submucosal neurons of rat and pig. 24 Although activation of opioid receptors inhibits electrolyte and fluid secretion, 2 the mechanism of inhibition is not clear. Intracerebroventricular administration of DOR agonist inhibits cholera toxin-stimulated jejunal secretion in rats via stimulation of sympathetic postganglionic fibers and activation of ␣2 adrenoceptors on submucosal neurons. 7 Our results suggest that such indirect mechanisms could operate in the large intestine, where the small number of DOR-expressing neurons may limit their influence on secretomotor activity. However, the extensive expression of DOR in secretomotor neurons of the small intestine indicates that agonists can inhibit secretion by direct action on submucosal neurons. Electrophysiological studies indicate that DOR agonists inhibit activity of submucosal neurons of guinea pig ileum and cecum, 25, 26 thereby suppressing secretion. 2 Enkephalinergic fibers innervating submucosal ganglia of the guinea pig small intestine originate in the myenteric plexus, with little evidence for expression by submucosal neurons. 27 Our inability to detect enkephalin in submucosal neurons supports these findings and suggests interaction between the myenteric and submucosal plexuses in any DOR-dependent regulation of secretion.
Location and Function of DOR in Excitatory and Inhibitory Motoneurons and Interneurons of the Myenteric Plexus
DOR agonists may inhibit motility by effects on central and enteric neurons. Peripheral SNC80 inhibits gastrointestinal propulsion in the mouse, and centrally penetrant but not peripherally restricted naloxone derivatives suppress this effect, suggesting a central mecha- 
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nism. 28 The observation that DOR knockdown in the rat brain inhibits the antipropulsive actions in the colon of peripheral SNC80 supports a central mechanism. 29 These reports are at variance with our demonstration that peripheral SNC80 directly activates (ie, internalizes) DOR in myenteric neurons. DOR agonists hyperpolarize these neurons, causing dysmotility and suppression of propulsion. 2 Intraventricular DOR agonists do not affect intestinal propulsion in rats, 30 and DOR agonists affect contractility and peristalsis of isolated rat and mouse colon, 31 supporting a direct, peripherally mediated mechanism. We detected DOR in excitatory (ChAT/SP-positive) and inhibitory (NOS/SOM-positive) myenteric motoneurons, and in nerve fibers innervating deep muscular plexus and circular muscle, supporting observations in rat and pig. 24 DOR was associated intimately with enkephalin-containing varicosities, and endogenous opioids activated (ie, internalized) DOR in myenteric neurons, suggesting that opioids suppress peristalsis by activating DOR on excitatory and inhibitory myenteric neurons. Opioid release from the rat colon declines during the inhibitory phase and increases during the excitatory phase of peristalsis. 6 Met-enkephalin inhibits release of mediators of ascending contraction (acetylcholine) 32 and descending relaxation (vasoactive intestinal polypeptide) 6 from isolated guinea pig ileum and rat colon, respectively. By releasing excitatory and inhibitory motoneurons from the inhibitory influence of endogenous opioids, DOR antagonists augment ascending contraction and descending inhibition of mouse colon. 5 The effects of enkephalins on inhibitory junction potentials in the dog duodenum are neurogenic and DOR-dependent, 9 suggesting that opioids activate DOR on inhibitory motoneurons that control neuromuscular transmission to circular muscle. The effects of opioids on inhibitory junction potentials are retained in preparations devoid of the myenteric plexus, supporting an action at inhibitory motor nerves within the circular muscle or deep muscular plexus. 9, 33 
Co-expression of Opioid Receptors by Enteric Neurons
Most enteric neurons that express DOR also express MOR, detected immunochemically and by Cy3-dermorphin uptake. DOR and MOR also are co-expressed in myenteric neurons of rat ileum, 34 and DOR colocalizes with KOR in myenteric neurons of the pig ileum. 24 Electrophysiological 35 and pharmacologic 36 studies support DOR/MOR co-expression by enteric neurons. In contrast to extensive DOR/MOR co-expression in enteric neurons, DOR and MOR are expressed by distinct neuronal populations of dorsal root ganglia neurons. 16 Although the functional relevance of DOR/MOR co-expression in enteric neurons remains to be determined, enkephalins may co-activate these receptors, which could amplify their inhibitory effects on motoneurons. 9 DOR/MOR heterodimerization also affects opioid affinity and G-protein signaling. 37 Whether these receptors dimerize in enteric neurons, and the functional relevance of their differential subcellular location (DOR mostly at the plasma membrane and MOR intracellularly or at the plasma membrane), remain to be determined.
Regulation of DOR in the Enteric Nervous System
Neuronal responsiveness to extracellular agonists requires receptor localization at the plasma membrane. Endocytosis attenuates G-protein-mediated signaling by depleting surface receptors, but some receptors interact in endosomes with ␤-arrestins, which transmit distinct signals. 10 DOR internalizes in the soma and axons of enteric neurons by clathrin/dynamin-mediated mechanisms, and traffics via early endosomes to lysosomes in the soma but to unidentified vesicles in the neurites. Although DOR will be degraded in lysosomes in the soma, the fate of the receptor in axons is unknown. Activated DOR is depleted from the cell surface for prolonged periods and replenishment of DOR at the surface of enteric neurons requires synthesis of new receptors. These observations are consistent with ubiquitination-mediated trafficking of DOR to lysosomes in cell lines. 11 Agonists that induce DOR endocytosis and down-regulation (SNC80) result in sustained tolerance to DOR-mediated analgesia, locomotor activation, and anxiolysis, whereas noninternalizing agonists (ARM390) induce tolerance only to DOR-mediated analgesia. 15 Thus, once activated by agonists that induce DOR endocytosis, enteric neurons would remain unresponsive to further challenges with DOR agonists for prolonged periods. DOR endocytosis and degradation could mediate tolerance to the antisecretory effects of enkephalins in the ileum after prolonged DOR activation. 38 However, chronic morphine induces tolerance to the contractile effects of opioids in the ileum but not the colon. 39 Further studies are required to define the mechanisms that regulate opioid-receptor subtypes in enteric neurons of different intestinal regions after acute and chronic activation.
Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at doi: 10.1053/j.gastro.2011.05.042.
Supplementary Materials and Methods
Materials
Cycloheximide, Dynasore, SNC80, naloxone hydrochloride, and naltrindole hydrochloride were from Tocris Biologicals (Ellisville, MO); Met-enkephalin was from Bachem (Torrance, CA); LysoTracker DND99 was from Invitrogen (Carlsbad, CA); peptidase and protease inhibitor cocktails were from Calbiochem/EMD Chemicals (Gibbstown, NJ); and other reagents were from SigmaAldrich (St. Louis, MO). An analogue of MOR-selective agonist dermorphin 1 was synthesized with Lys and Cys at positions 7 and 8, respectively (Tyr-D-Ala-Phe-Gly-TyrPro-Lys-Cys-NH 2 ; [Lys, 7 Cys 8 ]dermorphin; CPC Scientific, San Jose, CA). Peptide was labeled with Cy3 maleimide (GE Healthcare, Piscataway, NJ) according to the manufacturer's instructions. Cy3-dermorphin was purified by reverse-phase high-performance liquid chromatography on a C18 column, and labeled peptide was quantified using unlabeled [Lys, 7 Cys 8 dermorphin standards. 2 
Western Blotting
Tissues were snap-frozen and sonicated in RIPA buffer containing protease inhibitors. Proteins (60 g) were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (12% gel) and transferred to polyvinylidene difluoride membranes. Membranes were incubated with GFP antibody, washed, and incubated with AlexaFluor680-conjugated secondary antibody (Invitrogen, 1:10,000, 1 h, room temperature). Proteins were detected using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE).
Tissue Collection and Immunofluorescence
Tissues were placed in phosphate-buffered saline (PBS) (0.1 mol/L, pH 7.4) containing nicardipine (1 mol/L), opened, and then fixed in paraformaldehyde (4%, PBS, overnight). Tissue for sectioning was cryoprotected in 30% sucrose (PBS, 0.1% sodium azide, overnight), embedded in optimal cutting temperature compound, and frozen sections were prepared (12 m). Whole-mounts of myenteric and submucosal plexuses were prepared as described. 3 Sections and whole-mounts were incubated in blocking buffer (10% normal horse serum, 0.1% Triton X-100 in PBS), and then incubated with primary antibodies (Supplementary Table 1 ). Preparations stained for neurofilament M were preincubated in 0.3% Triton X-100 in PBS for 3 days before antibody application. 4 Tissues were washed, incubated with secondary antibodies coupled to fluorescein isothiocyanate, Rhodamine Red X, or Cy5 (donkey IgG, 1:200, 1 h, room temperature; Jackson Immunoresearch, West Grove, PA), and mounted. LysoTracker was used according to the manufacturer's directions.
Primary Cultures of Myenteric Neurons
Segments of ileum or distal colon were placed in ice-cold Hanks balanced salt solution containing nicardipine (1 mol/L) and antibiotic/antimycotic solution (1:100 dilution; 25 g/mL amphotericin B; 10,000 U/mL penicillin, and 10 mg/mL streptomycin). The muscularis externa and myenteric plexus were removed by sharp dissection, and digested with collagenase type IA (1 mg/mL) and DNase IV (0.1 mg/mL, 150 kU) in Dulbecco's modified Eagle medium (1 h, 37°C, constant agitation). 5 Tissue was digested with trypsin (0.25% solution with ethylenediaminetetraacetic acid, 5-10 min, 37°C). Digestion was terminated by adding 20% fetal bovine serum and soybean trypsin inhibitor (10 mg/ mL) followed by centrifugation. A single-cell suspension was achieved by trituration. Neurons were plated onto poly-L-lysine/laminin-coated coverslips, and were cultured in Dulbecco's modified Eagle medium supplemented with normal horse serum (5%), fetal bovine serum (5%), L-glutamine (2 mmol/L), antibiotic/antimycotic, and N1 neuronal supplement (1:100). Cytosine arabinoside (1 mol/L) was included in the culture medium from day 2 onward to inhibit proliferation of non-neuronal cells.
Imaging
Specimens were examined using a Zeiss Axiovert 200M microscope and Zeiss LSM510 META confocal system. Images were captured with 40ϫ (Plan-Neofluar/ 1.3), 63ϫ, or 100ϫ (Plan-Apochromat/1.4) objectives, with 1024 ϫ 1024 pixel resolution. To directly observe DOReGFP in cultured neurons, coverslips were mounted in a temperature-controlled open chamber containing Hank's balanced salt solution with 0.1% bovine serum albumin and 20 mmol/L HEPES (pH 7.4, 37°C). Expression of GFP relative to the total neuronal population and functional neuronal subtypes was determined by co-labeling with neurochemical markers. 6, 7 Counts were made from captured images (Ն20 neurons analyzed per preparation, n Ն 3 mice per marker and region). Neuron diameter was measured along the longest axis using Zeiss LSM Image. The subcellular distribution of DOReGFP was analyzed using ImageJ (National Institutes of Health, Bethesda, MD). 3 Supplementary 
